Literature DB >> 26893353

Identification of a small-molecule ligand of the epigenetic reader protein Spindlin1 via a versatile screening platform.

Tobias Wagner1, Holger Greschik2, Teresa Burgahn1, Karin Schmidtkunz1, Anne-Kathrin Schott2, Joel McMillan2, Lina Baranauskienė3, Yan Xiong4, Oleg Fedorov5, Jian Jin4, Udo Oppermann6, Daumantas Matulis3, Roland Schüle7, Manfred Jung8.   

Abstract

Epigenetic modifications of histone tails play an essential role in the regulation of eukaryotic transcription. Writer and eraser enzymes establish and maintain the epigenetic code by creating or removing posttranslational marks. Specific binding proteins, called readers, recognize the modifications and mediate epigenetic signalling. Here, we present a versatile assay platform for the investigation of the interaction between methyl lysine readers and their ligands. This can be utilized for the screening of small-molecule inhibitors of such protein-protein interactions and the detailed characterization of the inhibition. Our platform is constructed in a modular way consisting of orthogonal in vitro binding assays for ligand screening and verification of initial hits and biophysical, label-free techniques for further kinetic characterization of confirmed ligands. A stability assay for the investigation of target engagement in a cellular context complements the platform. We applied the complete evaluation chain to the Tudor domain containing protein Spindlin1 and established the in vitro test systems for the double Tudor domain of the histone demethylase JMJD2C. We finally conducted an exploratory screen for inhibitors of the interaction between Spindlin1 and H3K4me3 and identified A366 as the first nanomolar small-molecule ligand of a Tudor domain containing methyl lysine reader.
© The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26893353      PMCID: PMC4872087          DOI: 10.1093/nar/gkw089

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  38 in total

1.  Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery.

Authors:  Mei-Chu Lo; Ann Aulabaugh; Guixian Jin; Rebecca Cowling; Jonathan Bard; Michael Malamas; George Ellestad
Journal:  Anal Biochem       Date:  2004-09-01       Impact factor: 3.365

2.  The cellular thermal shift assay for evaluating drug target interactions in cells.

Authors:  Rozbeh Jafari; Helena Almqvist; Hanna Axelsson; Marina Ignatushchenko; Thomas Lundbäck; Pär Nordlund; Daniel Martinez Molina
Journal:  Nat Protoc       Date:  2014-08-07       Impact factor: 13.491

3.  Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair.

Authors:  Maria Victoria Botuyan; Joseph Lee; Irene M Ward; Ja-Eun Kim; James R Thompson; Junjie Chen; Georges Mer
Journal:  Cell       Date:  2006-12-29       Impact factor: 41.582

4.  Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction.

Authors:  Hacer Karatas; Elizabeth C Townsend; Denzil Bernard; Yali Dou; Shaomeng Wang
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

5.  The demethylase JMJD2C localizes to H3K4me3-positive transcription start sites and is dispensable for embryonic development.

Authors:  Marianne Terndrup Pedersen; Karl Agger; Anne Laugesen; Jens V Johansen; Paul A C Cloos; Jesper Christensen; Kristian Helin
Journal:  Mol Cell Biol       Date:  2014-01-06       Impact factor: 4.272

6.  1-anilino-8-naphthalene sulfonate as a protein conformational tightening agent.

Authors:  D Matulis; C G Baumann; V A Bloomfield; R E Lovrien
Journal:  Biopolymers       Date:  1999-05       Impact factor: 2.505

7.  Structural plasticity of methyllysine recognition by the tandem tudor domain of 53BP1.

Authors:  Qiong Tong; Gaofeng Cui; Maria Victoria Botuyan; Scott B Rothbart; Ryo Hayashi; Catherine A Musselman; Namit Singh; Ettore Appella; Brian D Strahl; Georges Mer; Tatiana G Kutateladze
Journal:  Structure       Date:  2015-01-08       Impact factor: 5.006

8.  Distinct mode of methylated lysine-4 of histone H3 recognition by tandem tudor-like domains of Spindlin1.

Authors:  Na Yang; Weixiang Wang; Yan Wang; Mingzhu Wang; Qiang Zhao; Zihe Rao; Bing Zhu; Rui-Ming Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-17       Impact factor: 11.205

9.  The BAH domain of ORC1 links H4K20me2 to DNA replication licensing and Meier-Gorlin syndrome.

Authors:  Alex J Kuo; Jikui Song; Peggie Cheung; Satoko Ishibe-Murakami; Sayumi Yamazoe; James K Chen; Dinshaw J Patel; Or Gozani
Journal:  Nature       Date:  2012-03-07       Impact factor: 49.962

10.  The histone code reader SPIN1 controls RET signaling in liposarcoma.

Authors:  Henriette Franz; Holger Greschik; Dominica Willmann; Luka Ozretić; Cordula Annette Jilg; Eva Wardelmann; Manfred Jung; Reinhard Buettner; Roland Schüle
Journal:  Oncotarget       Date:  2015-03-10
View more
  21 in total

Review 1.  Cellular analysis of the action of epigenetic drugs and probes.

Authors:  Mirjam Hau; Fides Zenk; A Ganesan; Nicola Iovino; Manfred Jung
Journal:  Epigenetics       Date:  2017-01-10       Impact factor: 4.528

2.  Developing Spindlin1 small-molecule inhibitors by using protein microarrays.

Authors:  Narkhyun Bae; Monica Viviano; Xiaonan Su; Jie Lv; Donghang Cheng; Cari Sagum; Sabrina Castellano; Xue Bai; Claire Johnson; Mahmoud Ibrahim Khalil; Jianjun Shen; Kaifu Chen; Haitao Li; Gianluca Sbardella; Mark T Bedford
Journal:  Nat Chem Biol       Date:  2017-05-15       Impact factor: 15.040

Review 3.  Targeting epigenetic protein-protein interactions with small-molecule inhibitors.

Authors:  Brian M Linhares; Jolanta Grembecka; Tomasz Cierpicki
Journal:  Future Med Chem       Date:  2020-06-19       Impact factor: 3.808

4.  A transcriptional coregulator, SPIN·DOC, attenuates the coactivator activity of Spindlin1.

Authors:  Narkhyun Bae; Min Gao; Xu Li; Tolkappiyan Premkumar; Gianluca Sbardella; Junjie Chen; Mark T Bedford
Journal:  J Biol Chem       Date:  2017-10-23       Impact factor: 5.157

5.  Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2.

Authors:  Kimberly D Barnash; Juliana The; Jacqueline L Norris-Drouin; Stephanie H Cholensky; Beau M Worley; Fengling Li; Jacob I Stuckey; Peter J Brown; Masoud Vedadi; Cheryl H Arrowsmith; Stephen V Frye; Lindsey I James
Journal:  ACS Comb Sci       Date:  2017-02-22       Impact factor: 3.784

Review 6.  Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation.

Authors:  Nilesh Zaware; Ming-Ming Zhou
Journal:  Curr Opin Chem Biol       Date:  2017-07-06       Impact factor: 8.822

Review 7.  Lysine methyltransferase inhibitors: where we are now.

Authors:  Alessandra Feoli; Monica Viviano; Alessandra Cipriano; Ciro Milite; Sabrina Castellano; Gianluca Sbardella
Journal:  RSC Chem Biol       Date:  2021-12-13

8.  Exploring aromatic cage flexibility of the histone methyllysine reader protein Spindlin1 and its impact on binding mode prediction: an in silico study.

Authors:  Chiara Luise; Dina Robaa; Wolfgang Sippl
Journal:  J Comput Aided Mol Des       Date:  2021-06-03       Impact factor: 3.686

Review 9.  Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine.

Authors:  Isabelle A Engelberg; Caroline A Foley; Lindsey I James; Stephen V Frye
Journal:  Curr Opin Chem Biol       Date:  2021-04-11       Impact factor: 8.972

10.  Structure-Based Design, Docking and Binding Free Energy Calculations of A366 Derivatives as Spindlin1 Inhibitors.

Authors:  Chiara Luise; Dina Robaa; Pierre Regenass; David Maurer; Dmytro Ostrovskyi; Ludwig Seifert; Johannes Bacher; Teresa Burgahn; Tobias Wagner; Johannes Seitz; Holger Greschik; Kwang-Su Park; Yan Xiong; Jian Jin; Roland Schüle; Bernhard Breit; Manfred Jung; Wolfgang Sippl
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.